Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
Egypt flag Egypt · Delayed Price · Currency is EGP
6.15
+0.08 (1.32%)
At close: Aug 25, 2026

EGX:RMDA Cash Flow Statement

Millions EGP. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
330.86298.46387.37244.86245.68181.09
Depreciation & Amortization
89.3892.2383.4372.8865.4846.18
Loss (Gain) From Sale of Assets
93.61-0.15-0.01-0.140.130.72
Asset Writedown & Restructuring Costs
2.562.562.51---
Stock-Based Compensation
47.7215.9516.2917.7717.85-
Provision & Write-off of Bad Debts
90.63104.811.443.813.640.11
Other Operating Activities
73.3760.949.242.42-8.44-10.39
Change in Accounts Receivable
-1,002-741.17-218.62-374.86-243.64-29.45
Change in Inventory
223.45-273.6-439.5130.97-88.5947.58
Change in Accounts Payable
270.2252.98276.3816.9768.5931.51
Change in Other Net Operating Assets
76.27343.33-435.45-59.17-31.35-25.99
Operating Cash Flow
295.76-43.67-306.92-44.529.35241.35
Operating Cash Flow Growth
-----87.84%-

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-144.46-155.9-64.93-91.05-34.38-52.67
Sale of Property, Plant & Equipment
1.130.21.720.180.020.02
Sale (Purchase) of Intangibles
-122.33-594.95-1.71-162.44-93.9-185.53
Investment in Securities
80.22237.39120.66194.68167.4768.06
Other Investing Activities
---93.84---
Investing Cash Flow
-185.44-513.26-38.09-58.6339.22-170.11

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-3,4341,9981,4211,2051,172
Total Debt Issued
2,3863,4341,9981,4211,2051,172
Short-Term Debt Repaid
--2,681-1,551-1,265-1,121-1,156
Long-Term Debt Repaid
--13.25-6.34-5.74-27.14-71.19
Total Debt Repaid
-2,212-2,694-1,558-1,271-1,149-1,228
Net Debt Issued (Repaid)
173.66740.47440.9149.7256.96-55.09
Issuance of Common Stock
8.21.883.232.11--
Repurchase of Common Stock
-----65.93-
Common Dividends Paid
-233.15-188.91-121.28-16.76-24.31-14.7
Financing Cash Flow
-51.28553.44322.86135.07-33.28-69.79

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-2.56-24.8234.480.4217.22-0.19
Net Cash Flow
56.48-28.3212.3232.3752.511.26

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
151.3-199.57-371.85-135.54-5.03188.68
Free Cash Flow Growth
------
Free Cash Flow Margin
3.45%-4.87%-13.43%-7.05%-0.34%15.14%
Free Cash Flow Per Share
0.07-0.10-0.18-0.07-0.000.09
Levered Free Cash Flow
-227.55-834.46-552.55-381.77-108.98-7.86
Unlevered Free Cash Flow
94.64-502.42-360.54-262.27-53.3249.03

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
497.23526.8294.66186.5284.8289.41
Cash Income Tax Paid
116.56101.8167.0760.6944.2928.91
Change in Working Capital
-432.37-618.46-817.2-386.09-29523.64